Posterior Uveitis - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Posterior Uveitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Posterior Uveitis - Pipeline Review, H1 2015', provides an overview of the Posterior Uveitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Posterior Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Posterior Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Posterior Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Posterior Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Posterior Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Posterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Posterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Posterior Uveitis - Overview 7
Pipeline Products for Posterior Uveitis - Comparative Analysis 8
Posterior Uveitis - Therapeutics under Development by Companies 9
Posterior Uveitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Posterior Uveitis - Products under Development by Companies 13
Posterior Uveitis - Companies Involved in Therapeutics Development 14
ForSight VISION4, Inc. 14
Neuroptis Biotech 15
pSivida Corp. 16
Regeneron Pharmaceuticals, Inc. 17
Virogenomics, Inc. 18
XOMA Corporation 19
Posterior Uveitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
fluocinolone acetonide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
gevokizumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NOP-3 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Peptides to Modulate TCR for Uveitis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
sarilumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
V-404 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Posterior Uveitis - Recent Pipeline Updates 40
Posterior Uveitis - Dormant Projects 52
Posterior Uveitis - Product Development Milestones 53
Featured News & Press Releases 53
Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis 53
Oct 03, 2012: Xoma Initiates Phase III Study Of Gevokizumab In Patients With Non-Infectious Uveitis Currently Controlled By Systemic Treatment 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Posterior Uveitis, H1 2015 7
Number of Products under Development for Posterior Uveitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Posterior Uveitis - Pipeline by ForSight VISION4, Inc., H1 2015 14
Posterior Uveitis - Pipeline by Neuroptis Biotech, H1 2015 15
Posterior Uveitis - Pipeline by pSivida Corp., H1 2015 16
Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 17
Posterior Uveitis - Pipeline by Virogenomics, Inc., H1 2015 18
Posterior Uveitis - Pipeline by XOMA Corporation, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Posterior Uveitis Therapeutics - Recent Pipeline Updates, H1 2015 40
Posterior Uveitis - Dormant Projects, H1 2015 52